SCIENCE
Pipeline

SCIENCE

Pipeline

Mechanism of Action
·
 When LAG-3 (primarily expressed on activated T cells) binds to its main ligand MHC class II, it suppresses T cell proliferation and activation, thereby reducing the immune response
·
 Our candidate blocks the interaction between LAG-3 and MHC II, thereby promoting T cell proliferation and restoring immune activity
·
 Dual blockade of PD-L1 and LAG-3 can enhance anti-tumor immune responses by enabling stronger and more sustained T cell activation through complementary mechanisms of action
Cancer-Immune Cell Engaging Efficacy (Melanoma)
PD-L1 x LAG-3 Dual TSIT
+ PBMC (200 nM)
Quantification of Empty Space Area: 91.95% @ 22h
PD-L1 + LAG-3 mAb Combi
+PBMC (200 nM)
Quantification of Empty Space Area: 33.83% @ 22h
Single-dose Toxicity Study

Single-dose toxicity testing up to 200 MPK showed no significant changes in body or organ weight of male and female rat, suggesting minimal safety concerns and a Maximum Tolerable Dose above 200 MPK relative to efficacy.

Mechanism of Action
·
 Anti-TIGIT blocks the interaction between TIGIT, expressed on T cells and NK cells, and its ligand CD155, thereby inhibiting the suppressive signaling in T cells and enhancing the cytotoxic activity of NK cells to boost antitumor immune responses.
·
 Dual blockade of PD-L1 and TIGIT enhances anti-tumor immunity by targeting complementary immune evasion pathways
Cancer-Immune Cell Engaging Efficacy (Melanoma)
PD-L1 x TIGIT Dual TSIT
+ PBMC (200 nM)
Quantification of Empty Space Area: 84.26% @ 22h
PD-L1 + TIGIT mAb Combi
+PBMC (200 nM)
Quantification of Empty Space Area: 36.58% @ 22h
Single-dose Toxicity Study

Single-dose toxicity testing up to 200 MPK showed no significant changes in body or organ weight of male and female rat, suggesting minimal safety concerns and a Maximum Tolerable Dose above 200 MPK relative to efficacy.

※ The above results were presented in our poster at the 2025 AACR Annual Meeting.
TME TME with PD-(L)1xVEGF Binding

PD-(L)1 x VEGF TSMT Development
·
 Since VEGF targets are ubiquitously distributed in the TME, we can expect the structural competitive advantages of T-sphaera in three dimensions vs. antibodies.
·
 After selecting VEGF pairing target(PD-1, PD-L1, etc.) we plan to establish TPP through competitive drug analysis.
Higher Structural Stability

Confirmed stability of T-sphaera in 30% DMSO solution which demonstrated higher structural stability than antibody
Higher Drug Loading Capacity

Based on the comparison of molecular weights before and after conjugation of the linker and payload, it was confirmed that exactly 24 linker-payloads were conjugated per T-sphaera.
Efficient Cell Penetration Capability

* Most ADCs are further limited by their slow internalization into the target cell (PDCs vs. ADCs: A New Frontier in Targeted Cancer Therapies and the Potential for Development Partnerships, ENDPOINTS NEWS)

Demonstrated higher cell penetration efficiency compared to ADCs